Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.
It has genuine struggles ahead, but it has some actual value in hand as well.
These two biotechs have important catalysts coming up in December.
Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END
/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug.
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate.
The company's lead diabetes and weight-loss therapy may benefit from a decision by Pfizer.
If it succeeds, it'll still face a battle for market share.